- Home
- SVII vs CRDL Comparison
SVII vs CRDL Comparison
Compare SVII & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- CRDL
- Stock Information
- Founded
- SVII 2021
- CRDL 2017
- Country
- SVII United States
- CRDL Canada
- Employees
- SVII N/A
- CRDL N/A
- Industry
- SVII Blank Checks
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVII Finance
- CRDL Health Care
- Exchange
- SVII Nasdaq
- CRDL Nasdaq
- Market Cap
- SVII 113.1M
- CRDL 102.0M
- IPO Year
- SVII 2022
- CRDL N/A
- Fundamental
- Price
- SVII $11.49
- CRDL $1.01
- Analyst Decision
- SVII
- CRDL Strong Buy
- Analyst Count
- SVII 0
- CRDL 3
- Target Price
- SVII N/A
- CRDL $9.00
- AVG Volume (30 Days)
- SVII 7.1K
- CRDL 221.7K
- Earning Date
- SVII 01-01-0001
- CRDL 05-13-2025
- Dividend Yield
- SVII N/A
- CRDL N/A
- EPS Growth
- SVII N/A
- CRDL N/A
- EPS
- SVII 0.33
- CRDL N/A
- Revenue
- SVII N/A
- CRDL N/A
- Revenue This Year
- SVII N/A
- CRDL N/A
- Revenue Next Year
- SVII N/A
- CRDL N/A
- P/E Ratio
- SVII $35.26
- CRDL N/A
- Revenue Growth
- SVII N/A
- CRDL N/A
- 52 Week Low
- SVII $11.01
- CRDL $0.77
- 52 Week High
- SVII $11.70
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- SVII 51.39
- CRDL 49.79
- Support Level
- SVII $11.44
- CRDL $0.77
- Resistance Level
- SVII $11.55
- CRDL $1.10
- Average True Range (ATR)
- SVII 0.01
- CRDL 0.10
- MACD
- SVII -0.00
- CRDL 0.02
- Stochastic Oscillator
- SVII 45.45
- CRDL 72.64
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.